| Ytd | -29.53% | |
| 1y | -26.35% |
| Open | 0.78 | Prev Close | 0.79 | Low | 0.77 | High | 0.82 | Mkt Cap | 22.85M |
| Vol | 348.69K | Avg Vol | 545.44K | EPS | -1.77 | P/E | -0.46 | Forward P/E | N/A |
| Beta | 1.39 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.94 | 200-d Avg | 1.23 | 1yr Est | 0.00 |
Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reducti